Universitaetsklinikum Tuebingen AöR

The Department für Frauengesundheit is running clinical trials focused on neoplasms, especially breast cancer and related breast neoplasms. This research is centered on improving treatment options for patients with early, advanced, and metastatic disease, with a strong emphasis on testing new therapies and comparing them with current standards of care.

• Studies in HR-positive, HER2-negative breast cancer are evaluating new treatment approaches for patients who have already received endocrine-based therapy.
• Research in metastatic breast cancer is assessing whether newer targeted treatments can improve disease control and survival.
• Trials in early breast cancer are examining whether novel endocrine strategies can reduce the risk of recurrence.

Overall, the site is contributing to clinical research that aims to refine how breast cancer is treated across different stages of disease, while helping identify more effective and better-tolerated options.

Another important area of work at this hospital in Tuebingen involves endometrial cancer. These studies are designed to improve outcomes after surgery by testing whether adding new treatment combinations can better prevent recurrence and extend survival in patients with high-risk disease.

• Research is focused on high-risk endometrial cancer after curative surgery, with attention to lowering the chance of the disease returning.
• The trials are also evaluating whether treatment combinations can improve disease-free survival and overall survival.

This work reflects a broader effort to strengthen post-surgical care for gynecologic cancers through more effective treatment strategies.

The site is also active in studies of triple negative breast cancer, a difficult-to-treat form of breast cancer. These trials are exploring whether combining newer immunotherapy and chemotherapy approaches can improve tumor response before surgery and reduce the risk of disease returning afterward.

• Research is examining treatment effectiveness in locally advanced TNBC.
• Key goals include improving pathologic complete response and event-free survival.

This line of research is especially important for patients with aggressive disease, where better treatment options are still needed.

Clinical trials at Universitaetsklinikum Tuebingen AöR are also examining treatment strategies for advanced hormone receptor-positive breast cancer, including patients with HER2-negative disease. These studies aim to improve how long treatments remain effective and to better understand resistance to current therapies.

• Trials in advanced breast cancer are comparing new options with standard care to see which approaches better control disease progression.
• Research is exploring ways to extend the benefit of endocrine therapy in patients with recurrent or metastatic disease.
• Some studies are also looking at the biology of treatment response and resistance in metastatic breast cancer.

Together, these studies support more personalized care for patients with advanced breast cancer by focusing on both treatment effectiveness and long-term disease management.